Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KG 207

Next Previous
Drug Profile

KG 207

Alternative Names: ABP-BBB; Anti-amyloid β fusion proteins; KAL-ABP; KAL-ABP-BBB; KG 207-M; KG-207

Latest Information Update: 01 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Research Council Canada
  • Developer KalGene Pharmaceuticals; National Research Council Canada
  • Class Antibodies; Antidementias
  • Mechanism of Action Amyloid beta-protein modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 05 Aug 2021 KalGene Pharmaceuticals plans a clinical trial of KG 207 for Alzheimer's disease (Parenteral)
  • 01 Aug 2021 Preclinical development in Alzheimer's disease is ongoing in Canada
  • 27 Jul 2020 Pharmacodynamics data from preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top